2,6-Di-tert-butylo-4-metylofenol. Dokumentacja proponowanych dopuszczalnych wielkości narażenia zawodowego

Soćko, Renata; Gromiec, Jan

doi:10.54215/PiMOSP/2.112.2022

Artykuł - szczegóły

Tytuł artykułu

2,6-Di-tert-butylo-4-metylofenol. Dokumentacja proponowanych dopuszczalnych wielkości narażenia zawodowego

Autorzy

Soćko Renata , Gromiec Jan

Treść / Zawartość

Pełne teksty:

Pobierz

Identyfikatory

DOI

10.54215/PiMOSP/2.112.2022

Warianty tytułu

2,6-Di-tert-butyl-4-methylphenol. Documentation of proposed values of occupational exposure limits (OELs)

Języki publikacji

Abstrakty

2,6-Di-tert-butylo-4-metylofenol (BHT) to organiczny związek chemiczny z grupy fenoli, który występuje w postaci białych kryształów lub jasnożółtego proszku. Substancja ta jest produkowana i/lub importowana do Europejskiego Obszaru Gospodarczego w ilości 10 000 ÷ 100 000 t/rok. BHT ze względu na właściwości przeciwutleniające jest stosowany m.in. w przemyśle spożywczym, farmaceutycznym i kosmetycznym w celu ochrony materiałów przed utlenianiem podczas długotrwałego przechowywania. Pomimo powszechnego stosowania BHT doniesienia o następstwach narażenia na tę substancję u ludzi są sporadyczne i ograniczają się zasadniczo do reakcji skórnych. BHT charakteryzuje się niską toksycznością ostrą po jednorazowym podaniu dożołądkowym lub skórnym. W badaniach doświadczalnych wykazano, że zarówno u gryzoni, jak i naczelnych wątroba jest narządem krytycznym działania związku. Badania działania mutagennego i genotoksycznego BHT przeprowadzone w warunkach in vitro i in vivo wykazały, że BHT nie stanowi istotnego ryzyka mutagennego i genotoksycznego dla człowieka. U potomstwa samic, które w okresie ciąży narażano na BHT drogą pokarmową, obserwowano wpływ związku na toksyczność rozwojową obejmującą skutki fetotoksyczne i embriotoksyczne. Nie stwierdzono wpływu narażenia na BHT na parametry reprodukcji. Podstawą do wyliczenia wartości NDS była wartość NOAEL wynosząca 25 mg/kg mc./dzień uzyskana z badania przewlekłego przeprowadzonego na szczurach. Po zastosowaniu kilku współczynników niepewności zaproponowano wartość NDS 2,6-di-tert-butylo-4-metylofenolu na poziomie 10 mg/m3 . Ustalona wartość powinna zabezpieczyć pracowników przed skutkami działania układowego i ewentualnego drażniącego związku. Nie ma podstaw do ustalenia wartości NDSCh oraz wartości dopuszczalnego stężenia w materiale biologicznym. Zakres tematyczny artykułu obejmuje zagadnienia zdrowia oraz bezpieczeństwa i higieny środowiska pracy będące przedmiotem badań z zakresu nauk o zdrowiu i inżynierii środowiska.

2,6-Di-tert-butyl-4-methylphenol (BHT) is an organic chemical compound from the group of phenols, which occurs in the form of white crystals or in the form of a light yellow powder. This substance is manufactured and/or imported into the European Economic Area in quantities of 10.000–100.000 t/year. BHT due to its antioxidant properties is used, e.g., in the food, pharmaceutical, cosmetic industries to protect materials from oxidation during long-term storage. Despite the widespread use of BHT, reports of the consequences of exposure to this substance in humans are sporadic and are generally limited to skin reactions. BHT is characterized by low acute toxicity after a single intragastric or cutaneous administration. Experimental studies have shown that in both rodents and primates, the liver is a critical organ of BHT action. In vitro and in vivo studies of the mutagenicity and genotoxic effects of BHT have shown that BHT does not pose a significant mutagenic and genotoxic risk to humans. In offspring of mammals who were exposed to BHT by the oral route during pregnancy, effects of the compound on developmental toxicity including fetotoxic and embryotoxic effects were observed. There was no effect of BHT exposure on reproduction parameters. The basis for calculating MAC was a NOAEL of 25 mg/kg/day obtained from a chronic study in rats. After applying several uncertainty factors, MAC of 2,6-di-tert-butyl-4-methylphenol of 10 mg/m3 was proposed. The established value should protect employees from the effects of systemic action and possible irritating relationship. There are no grounds for establishing the value of STEL and the value of the permissible concentration in biological material. This article discusses the problems of occupational safety and health, which are covered by health sciences and environmental engineering.

Słowa kluczowe

2,6-di-tert-butylo-4-metylofenol toksyczność narażenie zawodowe NDS nauki o zdrowiu inżynieria środowiska

butylated hydroxytoluene toxicity occupational exposure MAC health sciences environmental engineering

Wydawca

Centralny Instytut Ochrony Pracy - Państwowy Instytut Badawczy

Czasopismo

Podstawy i Metody Oceny Środowiska Pracy

Rocznik

2022

Tom

Nr 2 (112)

Strony

27--67

Opis fizyczny

Bibliogr. 197 poz., rys., tab.

Twórcy

autor

Soćko Renata

renata.socko@imp.lodz.pl

Instytut Medycyny Pracy im. prof. dr. med. Jerzego Nofera 91-348 Łódź, ul. św. Teresy od Dzieciątka Jezus 8 POLAND

autor

Gromiec Jan

Instytut Medycyny Pracy im. prof. dr. med. Jerzego Nofera 91-348 Łódź, ul. św. Teresy od Dzieciątka Jezus 8 POLAND

https://orcid.org/https%3A//orcid.org/0002-0002-0550-6655+

Bibliografia

1. Abe S., Sasaki M. (1977). Chromosome aberrations and sister chromatid exchanges in Chinese hamster cells exposed to various chemicals. J. Natl. Cancer Inst. 58(6), 1635–1641.
2. ACGIH, American Conference of Governmental Industrial Hygienists (2001). Butylated hydroxytoluene (on CD-ROM TLVs and BEIs with 7th ed. Documentation).
3. ACGIH, American Conference of Governmental Industrial Hygienists (2021). Guide to Occupational Exposure Values. Cincinnati, USA.
4. Adamson I.Y., Bowden D.H., Cote M.G. i in. (1977). Lung injury induced by butylated hydroxytoluene: cytodynamic and biochemical studies in mice. Lab. Invest. 36(1), 26–32.
5. Alarie Y. (1981). Bioassay for evaluating the potency of airborne sensory irritants and predicting acceptable levels of exposure in man. Food Cosmet. Toxicol. 19(5), 623–626 [cyt. za: MAK 2007].
6. Allen J.R., Engblom J.F. (1972). Ultrastructural and biochemical changes in the liver of monkeys given butylated hydroxy-toluene and butylated hydroxyanisole. Food Cosmet. Toxicol. 10(6), 769–779.
7. Allen J.R. (1976). Long‐term antioxidant exposure effects on female primates. Arch. Environ. Health 31(1), 47–50.
8. Ames S.R., Ludwig M.I., Swanson W.J. i in. (1956). Effect of DPPD, methylene blue, BHT and hydroquinone on repr oductive process in the rat. Proc. Soc. Exp. Biol. Med. 93(1), 39–42.
9. Ande rstam B., Segerback D., Ehrenberg L. (1982). Studium av DNA‐syntheshastigheten som mått på promotorverkan av partiklar från koleldat kraftverk. KHM Teknisk Rapport 29, Stockholm Universitet.
10. Bardazzi F., Misciali C., Borrello P. i in. (1988). Contact dermatitis due to antioxidants. Contact Dermatitis 19(5), 385–386.
11. Bauer A.K., Dwyer‐Nield L.D., Hankin J.A. i in. (2001). The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion‐sensitive BALB/cByJ mice but not in promotion‐resistant CXB4 mice. Toxicology 169(1), 1–15.
12. Bentley‐Phillips B., Bayles M.A.H. (1974). Butylated hydroxytoluene as a skin lightener. Arch. Dermatol. 109(2), 216–217.
13. de Boer E.M., van Ketel W.G., Bruynzeel D.P. (1989). Dermatoses in metal workers: (II). Allergic contact dermatitis. Contact Dermatitis 20(4), 280–286.
14. Bohrman J.S., Burg J.R., Elmore E. i in. (1988). Interlaboratory studies with the Chinese hamster V79 cell metabolic cooperation assay to detect tumor-promoting agents. Environ. Mol. Mutagen. 12(1), 33–51.
15. Bomhard E.M., Bremmer J.N., Herbold B.A. (1992). Review of the mutagenicity/genotoxicity of butylated hydroxytoluene. Mutat. Res. 277(3), 187–200 [cyt. za: ACGIH 2001].
16. Bonin A.M., Baker R.S.U. (1980). Mutagenicity testing of some approved food additives with the Salmonella/microsome assay. Food Technol. Aust. 32(12), 608–611.
17. Botterweck A.A.M., Verhagen H., Goldbohm R.A. i in. (2000). Intake of butylated hydroxyanisole and butylated hydroxytoluene and stomach cancer risk: results from analyses in the Netherlands Cohort Study. Food Chem. Toxicol. 38(7), 599–605.
18. Brams A., Buchet J.P., Crutzen‐Fayt M.C. i in. (1987). A comparative study, with 40 chemicals, of the efficiency of the Salmonella assay and the SOS chromotest (kit procedure). Tox-icol. Lett. 38(1–2), 123–133.
19. Briggs D., Lok E., Nera E.A. i in. (1989). Short‐term effects of butylated hydroxytoluene on the Wistar rat liver, urinary bladder and thyroid gland. Cancer Lett. 46(1), 31–36.
20. Bronaugh R.L, Stewart R.F, Storm J.E. (1989). Extent of cutaneous metabolism during percutaneous absorption of xenobiotics. Toxicol. Appl. Pharmacol. 99(3), 534–543.
21. Bronaugh R.L., Collier S.W., Storm J.E. i in. (1990a). In vitro absorption/metabolism studies in human and animal skin. [In:] R.C. Scott, R.H. Guy, J. Hadgraft (eds.). Prediction of percutaneous penetration, methods, measurements, modelling. IBC Technical Services Ltd, 58–72.
22. Bronaugh R.L., Collier S.S.W., Storm J.E. i in. (1990b). In vitro evaluation of skin absorption and metabolism. J. Toxicol. Cut. Ocular. Toxicol. 8(4), 453–467.
23. Brown W.D., Johnson A.R., O’Halloran M.W. (1959). The effect of the level of dietary fat on the toxicity of phenolic antioxidants. Aust. J. Exp. Biol. Med. Sci. 37, 533–548.
24. Bruce W.R., Heddle J.A. (1979). The mutagenic activity of 61 agents as determined by the micronucleus, Salmonella, and sperm abnormality assays. Can. J. Genet. Cytol. 21(3), 319–334.
25. BUA (Beratergremium fur Altstoffe), (GDCh‐Advisory Committee on Existing Chemicals of Environmental Relevance). (1991). Butylated hydroxytoluene. BUA Report 58 S. Hirzel Verlag, Stuttgart [cyt. za: MAK 2007].
26. BUA (GDCh-Advisory Committee on Existing Chemicals) (2000). BUA Report 219, Supplementary Report VI S. Hirzel Verlag, Stuttgart [cyt. za: MAK 2007].
27. Budunova I.V., Mittelman L.A., Belitsky G.A. (1989). Identification of tumor promoters by their inhibitory effect on intercellular transfer of lucifer yellow. Cell Biol. Toxicol. 5(1), 77–89.
28. CEFIC‐EBMA (1989). Dose ranging experiment on the role of hepatocellular injury in the chronic toxicity of BHT. Final report 7/88/TX, Robens Institute of Health and Safety, University of Surrey, Surrey, UK [cyt. za: MAK 2007].
29. CEFIC‐EBMA (1990). Long term toxicity study effects produced by BHT in a two generation study: an overview of results obtained to date. Robens Institute of Health and Safety, University of Surrey, Surrey, UK [cyt. za: MAK 2007].
30. CEFIC‐EBMA (1994). The role of hepatocellular injury in the chronic toxicity of BHT: two generation Wistar albino rat study. Final Report RI93/TOX/0020, Robens Institute of Health and Safety, University of Surrey, Surrey, UK [cyt. za: MAK 2007].
31. Chen C., Shaw Y.S. (1974). Cyclic metabolic pathway of a butylated hydroxytoluene by rat liver microsomal fractions. Biochem. J. 144(3), 497–501.
32. Chipman J.K., Davies J.E., Paterson P. (1987). Mechanisms of butylated hydroxytoluene‐mediated modulation of 2‐acetylaminofluorene mutagenicity in rat and human hepatocyte/ Salmonella assays. Mutat. Res. 187(3), 105–112.
33. Chipman J.K., Davies J.E. (1988). Reduction of 2-acetylaminofluorene-induced unscheduled DNA synthesis in human and rat hepatocytes by butylated hydroxytoluene. Mutat. Res. 207(3–4), 193–198.
34. Clegg D.J. (1965). Absence of teratogenic effect of butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) in rats and mice. Food Chem. Toxicol. 3(3), 387–403.
35. Courtheoux S.I., Wepierre J., Marty J.P. (1985). Topical pharmacokinetics of [14C] butylated hydroxytoluene in the guinea pig. Dermatology 9, 153–164.
36. Cumming R.B., Walton M.F., Kelley E.M. i in. (1976). The lack of induction of specific-locus mutations in mice by long-term exposure to high levels of butylated hydroxytoluene. Biology division annual progress report for period ending June 30, 1976, Oak Ridge National Laboratory, Oak Ridge, Tennessee, USA, ORNL-5195, 20–22.
37. Daniel J.W., Gage J.C. (1965).The absorption and excretion of butylated hydroxytoluene (BHT) in the rat. Food Cosmet. Toxicol. 3(3), 405–415.
38. Daniel J.W., Gage J.C., Jones D.I. i in. (1967). Excretion of butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA) by man. Food Cosmet. Toxicol. 5(4), 475–479.
39. Daniel J.W., Gage J.C., Jones D.I. (1968). The metabolism of 3,5-di-tert-butyl-4-hydroxytoluene in the rat and in man. Biochem. J. 106(4), 783–790.
40. Daugherty J.P., Davis S., Yielding K.L. (1978). Inhibition by butylated hydroxytoluene of excision repair synthesis and semiconservative DNA synthesis. Biochem. Biophys. Res. Commun. 80(4), 963–969.
41. Daugherty J.P. (1984). Mechanism of butylated hydroxytoluene-associated modification of diethyl-nitrosamine-induced squamous stomach carcinoma. Food Chem. Toxicol. 22(12), 951–961.
42. Daugherty P.J., Franks H. (1986). Effect of monocyclic derivatives on DNA repair in human lymphocytes. Res. Commun. Chem. Pathol. Pharmacol. 54(1), 133–136.
43. Deichmann W.B., Gables C., Clemmer J.J. i in. (1955). Toxicity of ditertiary‐butylmethylphenol. Arch. Ind. Health 11, 93–101 [cyt. za: ACGIH 2001].
44. Dellarco V.L., Mavournin K.H., Tice R.R. (1985). Aneuploidy and health risk assessment: current status and future directions. Environ. Mutagen. 7(3), 405–424.
45. Dissanayake M., Powell S.M. (1989). Allergic contact dermatitis from BHT in leg ulcer patients. Contact Dermatitis 21(3), 195.
46. Djurhuus R., Lillehaug J.R. (1982). Butylated hydroxytoluene: tumor‐promoting activity in an in vitro two‐stage carcinogenesis assay. Bull. Environ. Contam. Toxicol. 29, 115–120.
47. Dwyer‐Nield L.D., Thompson J.A., Peljak G. i in. (1998). Selective induction of apoptosis in mouse and human lung epithelial cell lines by the tert‐butyl hydroxylated metabolite of butylated hydroxytoluene: a proposed role in tumor promotion. Toxicology 130(2–3), 115–127.
48. ECHA, European Chemicals Agency (2021). Registered Substances. 2,6-Di-tert-butyl-p-cresol (CAS number: 128-37-0, EC number: 204-881-4), https://echa.europa.eu/pl/registration-dossier/-/registered-dossier/15975/7/3/4 [dostęp: 12.10.2021].
49. El‐Rashidy R., Niazi S. (1980). Comparative pharmacokinetics of butylated hydroxyanisole and butylated hydroxytoluene in rabbits. J. Pharm. Sci. 69(12), 1455–1457.
50. Endocrine disruptor assessment list (2021). ECHA, https:// echa.europa.eu/pl/ed-assessment, aktualizacja: 6.04.2021 [dostęp: 6.04.2021].
51. Ennever F., Rosenkranz S. (1986). Short-term test results for NTP noncarcinogens: an alternate, more predictive battery. Environ. Mutagen. 8(6), 849–865.
52. Epstein S.S., Shafner H. (1968). Chemical mutagens in the human environment. Nature 219, 385–387.
53. Epstein S.S., Arnold E., Andrea J. i in. (1972). Detection of chemical mutagens by the dominant lethal assay in the mouse. Toxicol. Appl. Pharmacol. 23(2), 288–325.
54. FDA, Food and Drug Administration (1972a). Teratologic evaluation of FDA 71–25 (butylated hydroxytoluene – ionol). Food and Drug Research Labs, Inc., National Technical Information Service PB‐ 221782. FDA, Food and Drug Administration (1972b). Study of mutagenic effects of ionol C. P. (butylated hydroxytoluene) (71-25). Stanford Research Institute, National Technical Information Service PB-221827 [cyt. za: MAK 2007].
55. FDA, Food and Drug Administration (1974). Teratologic evaluation of compound FDA 71–25 butylated hydroxytoluene (ionol) in rabbits. Food and Drug Research Labs, Inc., National Technical Information Service PB‐ 267201 [cyt. za: MAK 2007].
56. FDA, Food and Drug Administration (1975). Mutagenic evaluation of compound FDA 71–25, butylated hydroxytoluene. Litton Bionetics, Inc., National Technical Information Services PB‐ 245487 [cyt. za: MAK 2007].
57. Ferreri A.M., Grilli M.P., Capucci A. i in. (1986). Effect of antioxidants on mutagenesis induced by DMBA in human cells. Nutr. Cancer 8(4), 267–272.
58. Final report on the safety assessment of BHT (2002). [No authors listed]. Int. J. Toxicol. 21(Suppl. 2), 19–94 [cyt. za: MAK 2007].
59. Fisherman E.W., Cohen G. (1973). Chemical intolerance to butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) and vascular response as an indicator and monitor of drug intolerance. Ann. Allergy 31(3), 126–133 [cyt. za: ACGIH 2001].
60. Flyvholm M.A., Menné T. (1990). Sensitizing risk of butylated bydroxytoluene based on exposure and effect data. Contact Dermatitis 23(5), 341–345 [cyt. za: ACGIH 2001].
61. Frawley J.P., Kohn F.E., Kay J.H. i in. (1965). Progress report on multigeneration reproduction studies in rats fed butylated hydroxytoluene (BHT). Food Cosmet. Toxicol. 3(3), 377–386.
62. Fujita H., Hiraga K. (1980). Effect of butylated hydroxytoluene on the mutagenicity of thiobendazole in the Salmonella/ microsome test. Ann Rep. Tokyo Metr. Res. Lab. Publ. Health. 31, 26–28.
63. Galloway S.M., Armstrong M.A., Reuben C. i in. (1987). Chromosome aberration and sister chromatid exchange in Chinese hamster ovary cells: evaluation of 108 chemicals. Environ. Mol. Mutagen. 10(Suppl. 10), 1–176 [cyt. za: ACGIH 2001].
64. Genium Publishing Corp. (1999). 2,6-Di-tert-butyl-p-cresol. [In:] Genium’s Handbook of Environmental, Health, and Safety Data for Common Hazardous Substances CD-ROM. McGraw-Hill, New York [cyt. za: ACGIH 20021].
65. GESTIS (2021). 2,6-Di-tert-butyl-p-cresol. GESTIS International Limit Values for chemical agents (Occupational exposure limits, OELs). IFA Institut für Arbeitsschutz der Deutschen Gesetzlichen Unfallversicherung, https://limitvalue.ifa.dguv.de/WebForm_ueliste2.aspx [dostęp: 13.10.2021].
66. GIS, Główny Inspektorat Sanitarny (2019). Baza danych prowadzona przez Wojewódzką Stację Sanitarno-Epidemiologiczną w Bydgoszczy zawierająca dane dotyczące ekspozycji pracowników na wybrane substancje chemiczne [dane nieopublikowane].
67. Goh C.L., Ho S.F. (1993). Contact dermatitis from dielectric fluids in electrodischarge machining. Contact Dermatitis 28(3), 134–138.
68. Grillo C.A., Dulout F.N. (1995). Cytogenetic evaluation of butylated hydroxytoluene. Mutat. Res. 345(1–2), 73–78 [cyt. za: ACGIH 2001].
69. Grillo C.A., Dulout F.N. (1997). The effect of butylated hydroxytoluene on the chromosomal damage induced by bleomycin in Chinese hamster ovary cells. Mutat. Res. 375(1), 83–89.
70. Grogan M.W. (1986). Toxicity from BHT ingestion (correspondence). West J. Med. 145(2), 245–246.
71. Guan X., Hardenbrook J., Fernstrom M.J. i in. (1995). Down‐ regulation by butylated hydroxytoluene of the number and function of gap junctions in epithelial cell lines derived from mouse lung and rat liver. Carcinogenesis 16(10), 2575–2582.
72. Guy R.H., Potts R.O. (1993). Penetration of industrial chemicals across the skin: a predictive model. Am. J. Ind. Med. 23(5), 711–719.
73. Han S.Y., Kim P.G., Park K.L. i in. (1993). A teratogenicity study on phenolic antioxidants in rats. Teratology 48, 507.
74. Hanada H. (2012). Phenolic antioxidant 2,6-di-tert-butyl-p-cresol (vitamin E synthetic analogue) does not inhibit 1,1ˋ-dimetyl-4,4ˋbipyridium dichloride (paraquat)-induced structural chromosomal damage in cultured leukocytes of the dark-spotted-frog Pelophylax (Rana) nigromaculatus. Hereditas 149(5), 173–177.
75. Hathaway D.E. (1966). Metabolic fate in animals of hindered phenolic antioxidants in relation to their safety evaluation and antioxidant function. Adv. Food Res. 15, 1–56.
76. Heil J., Reifferscheid G. (1992). Detection of mammalian carcinogens with an immunological DNA synthesis-inhibition test. Carcinogenesis 13(12), 2389–2394.
77. Heil J., Reifferscheid G., Waldmann P. i in. (1996). Genotoxicity of dental materials. Mutat. Res. 368(3–4), 181–194.
78. Hiraga K. (1978). Chronic toxicity, teratogenicity and mutagenicity tests with dibutyl hydroxy toluene. Tokyo Metropolitan Research Laboratory of Public Health, Tokyo, Japan.
79. Hirose M., Shibata M., Hagiwara A. i in. (1981). Chronic toxicity of butylated hydroxytoluene in Wistar rats. Food Cosmet. Toxicol. 19, 147–151.
80. Holder G.M., Ryan A.J., Watson T.R. i in. (1970a). The metabolism of butylated hydroxy-toluene, (3,5-di-t-butyl-4-hydroxytoluene) in man. J. Pharm. Pharmacol. 22(5), 375–376.
81. Holder G.M., Ryan A.J., Watson T.R. i in. (1970b). The biliary metabolism of butylated hydroxytoluene (3,5‐di‐t‐butyl‐4‐ hydroxytoluene) and its derivatives in the rat. J. Pharm. Pharmacol. 22(11), 832–838.
82. IARC, International Agency for Research on Cancer (1986). IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans. Vol. 40, Some naturally occurring and synthetic food components, furocoumarins, and ultraviolet radiation, 161–170. IARC, Lyon, France.
83. Ichikawa H., Fujii T., Kobayashi H. i in. (1972). Toxicological potentiation studies on food additives (II); subchronic oral toxicity of butylated hydroxytoluene, sodium nitrite and their combination in rats. Kenkyu Nenpo-Tokyo-toritsu Eisei 29, 345–371.
84. Inai K., Kobuke T., Nambu S. i in. (1988). Hepatocellular tumorigenicity of butylated hydroxytoluene administered orally to B6C3F1 mice. Jpn. J. Cancer. Res. 79(1), 49–58.
85. Ishidate M., Odashima S. (1977). Chromosome tests with 134 compounds on Chinese hamster cells in vitro: a screening for chemical carcinogens. Mutat. Res. 48(3–4), 337–354.
86. Ishidate M., Yoshikawa K., Sofuni T. (1980). A primary screening for mutagenicity of food additives in Japan. Mutagen. Toxicol. 3, 82–90.
87. Ishidate M. (1983). Butylated hydroxytoluene: chromosomal aberration test in vitro. Realize Inc, Japan, 80. Ishidate M., Sofuni T., Yoshikawa K. i in. (1984). Primary mutagenicity screening of food additives currently used in Japan. Food Chem. Toxicol. 22(8), 623–636.
88. Janiski S., Fiebig A., Sznitowska M. (2008). Farmacja stosowana. Podręcznik dla studentów farmacji. Warszawa, Wydawnictwo Lekarskie PZWL.
89. JECFA, The Joint FAO/WHO Expert Committee on Food Additives (1980). Butylated hydroxytoluene. [In:] Toxicological evaluation of certain food additives, WHO Additive Series No. 15, 1106–1115. FAO/WHO, Geneva, Switzerland [cyt. za: MAK 2007].
90. Johnson A.R. (1965). A re‐examination of the possible teratogenic effects of butylated hydroxytoluene (BHT) and its effect on the reproductive capacity of the mouse. Food Cosmet. Toxicol. 3(3), 371–375.
91. Kamra O.P. (1973). Radiosensitizing property of butylated hydroxytoluene in Drosophila sperm. Int. J. Radiat. Biol. 23(3), 295–297.
92. Kamra O.P., Rajaraman R. (1973). Potentiation of gamma-ray induced sex-linked recessive lethal mutations by butylated hydroxytoluene (BHT) in Drosophila melanogaster. Mutat. Res. 21, 9.
93. Kanerva L., Jolanki R., Estlander T. (1997). Allergic and irritant patch test reactions to plastic and glue allergens. Contact Dermatitis 37(6), 301–302.
94. Kanerva L., Jolanki R., Alanko K. i in. (1999). Patch‐test reactions to plastic and glue allergens. Acta Derm. Venereol. 79(4), 296–300.
95. Karamova N.S., Il’inskaia O.N., Ivanchenko O.B. i in. (1997). [Genotoxic effects of tonarol]. Genetika 33, 1310–1312.
96. Karplyuk I.A. (1960). [Elementary raw fats containing phenolic antioxicants: an elevation from the point of view of hygiene]. Vorp. Pitan. 19, 67.
97. Kawachi T., Komatsu T., Kada T. i in. (1980). Results of recent studies on the relevance of various short-term screening tests in Japan. [In:] G.M. Williams, R. Kroes, H.W. Waaijers i in. (eds.). The predictive value of short-term screening tests in carcinogenicity evaluation, 253, 253–269.
98. Kawano S., Nakao T., Hiraga K. (1981). Strain differences in butylated hydroxytoluene‐induced deaths in male mice. Toxicol. Appl. Pharmacol. 61(3), 475–479.
99. Kerr R., Lefevre A., Lane B. i in. (1966). Liver growth induced by butylated hydroxytoluene (BHT). Clin. Res. 14, 299.
100. Kinae N., Hashizume T., Makita T. i in. (1981). Studies on the toxicity of pulp and paper mill effluents: 1. Mutagenicity of the sediment samples derived from Kraft paper mills. Water Res. 15(1), 17–24.
101. Koch P. (1996). Kontaktallergien bei Metallarbeitern [Contact allergies in metal workers]. Dermatosen Beruf Umwelt 44, 62–67.
102. Kupfer R., Dwyer‐Nield L.D., Malkinson A.M. i in. (2002). Lung toxicity and tumor promotion by hydroxylated derivatives of 2,6‐di‐tert‐butyl‐4‐methylphenol (BHT) and 2‐tert‐ butyl‐4‐methyl‐6‐iso‐propylphenol: correlation with quinone methide reactivity. Chem. Res. Toxicol. 15(8), 1106–1112.
103. Ladomery L.G., Ryan A.J., Wright S.E. (1967a). The excretion of [14C] butylated hydroxytoluene in the rat. J. Pharm. Pharmacol. 19(6), 383–387
104. Ladomery L.G., Ryan A.J., Wright S.E. (1967b). The biliary metabolites of butylated hydroxytoluene in the rat. J. Pharm. Pharmacol. 19(6), 388–394.
105. Lane B., Lieber C.S. (1967). Effects of butylated hydroxytoluene on the ultrastructure of rat hepatocytes. Lab. Invest. 16, 342–348.
106. Latino-Martel P., Chaumontet C., François V. i in. (1988). An in vivo – in vitro model to study the cellular transformation elicited by liver tumor promoters: application to phenobarbital, butylated hydroxytoluene and butylated hydroxyanisole. [In:] A. Guillouzo (ed.). Liver cells and drugs, Colloque INSERM/John Libbey Eurotext Ltd., 164, 459–464.
107. Le Coz C.J., Schneider G.A. (1998). Contact dermatitis from tertiary‐butylhydroquinone in a hair dye, with cross‐sensitivity to BHA and BHT. Contact Dermatitis 39(1), 39–40.
108. MAK (2007). 2,6‐Di‐tert‐butyl‐p‐cresol (BHT). MAK Value Documentation, Vol. 23. First published: 31 January 2012, https://doi.org/10.1002/3527600418.mb12837e0023 [dostęp: 11.05.2021].
109. Mallette F.S., von Haam E. (1952). Studies on the toxicity and skin effects of compounds used in the rubber and plastics industries: I. Accelerators, activators, and antioxidants. AMA Arch. Ind. Hyg. Occup. Med. 5(4), 311– 317.
110. Marino A.A., Mitchell J.T. (1972). Lung damage in mice following intraperitoneal injection of butylated hydroxytoluene. Proc. Soc. Exp. Biol. Med. 140(1), 122–125.
111. Marty J.P., Courtheoux S., Maibach H. i in. (1984). Percutaneous absorption of 14C‐butylated hydroxytoluene and 14C‐malathion in the guinea pig: effect of repeated skin administration. Biopharm Pharmacokinet. Eur. Congr. 2nd, 1, 272–281.
112. Masubuchi M., Takahashi A., Takahashi O. i in. (1976). The cytogenetic studies and dominant lethal tests of long term administration with butylated hydroxytoluene (BHT) and linear alkyl-benzene sulfonate (LAS) in mice and rats. Ann. Rep. Tokyo Metr. Res. Lab. Publisher Health 27, 100–104.
113. Maxwell W.A., Newell G.W. (1974). Screening techniques for environmental mutagens. [In:] L. Prakash, F. Sherman, M.W. Miller i in. (eds.). Molecular and environmental aspects of mutagenesis, Charles C Thomas Publisher, Springfield, Ill, USA, 223–252.
114. McFarlane M. (1994). Butylated hydroxytoluene treatment prior to and during pregnancy in the rat: effects of subsequent exposure on hepatic biochemical and histological parameters in male offspring. Doctoral thesis, The Robens Institute, University of Surrey, Guildford, UK.
115. McFarlane M., Price S.C., Cottrell S. i in. (1997). Hepatic and associated response of rats to pregnancy, lactation and simultaneous treatment with butylated hydroxytoluene. Food. Chem. Toxicol. 35(8), 753–767.
116. McGregor D.B., Brown A., Cattanach P. i in. (1988). Responses of the L5178Y tk+/tk– mouse lymphoma cell forward mutation assay to coded chemicals: II. 18 coded chemicals. Environ. Mol. Mutagen. 11(1), 91–118.
117. Meneghini C.L., Rantuccio F., Lomuto M. (1971). Additives, vehicles and active drugs of topical medicaments as causes of delayed‐type allergic dermatitis. Dermatologica 143(3), 137–147.
118. Meyer O., Blom L., Olsen P. (1978). Influence of diet and strain of rat on kidney damage observed in toxicity studies. Arch. Toxicol. 1, 355–358.
119. Meyer O., Hansen E. (1980). Behavioural and developmental effects of butylated hydroxytoluene dosed to rats in utero and in the lactation period. Toxicology 16(3), 247–258.
120. Meyer O., Blom L., Søndergaard D. (1982). The influence of minerals and protein on the nephrocalcinosis potential for rats of semisynthetic diets. Lab. Anim. 16(3), 271–273.
121. Meynadier J.M., Meynadier J., Colmas A. i in. (1982). Allergie aux conservateurs [Allergy to preservatives]. Ann. Dermatol. Venereol. (Paris) 109, 1017–1023.
122. Miyagawa M., Takasawa H., Sugiyama A. i in. (1995). The in vivo – in vitro replicative DNA synthesis (RDS) test with hepatocytes prepared from male B6C3F1 mice as an early prediction assay for putative nongenotoxic (Ames‐negative) mouse hepatocarcinogens. Mutat. Res. 343(2–3), 157–183.
123. Miyakawa Y., Takahashi M., Furukawa F. i in. (1986). Pneumotoxicity of butylated hydroxytoluene applied dermally to CD‐1 mice. Toxicol. Lett. 34(1), 99–105.
124. Morita K., Ishigaki M., Abe T. (1981). Mutagenicity of materials related with cosmetics. J. Soc. Cosmet. Chem. Jp. 15(3), 243–253.
125. Mortelmans K., Haworth S., Lawlor T. i in. (1986). Salmonella mutagenicity tests: II. Results from the testing of 270 chemicals. Environ. Mutagen. 8(Suppl. 7), 1–119 [cyt. za: ACGIH 2001].
126. Motolese A., Seidenari S. (1994). Patch test reading: a comparison between 2 application methods. Contact Dermatitis 30, 49–50.
127. Nagai F., Ushiyama K., Kano I. (1993). DNA cleavage by metabolites of butylated hydroxytoluene. Arch. Toxicol. 67(8), 552–557.
128. Nakagawa Y., Hiraga K., Suga T. (1980). Biological fate of butylated hydroxytoluene (BHT) – binding of BHT to nucleic acid in vivo. Biochem. Pharmacol. 29, 1304–1306.
129. Nakagawa Y., Hiraga K., Suga T. (1981). On the mechnism of binding of 14C-labeled butylated hydroxytoluene to liver ribonucleic acid in vivo. Biochem. Pharmacol. 30(22), 3132–3133.
130. Nakagawa Y., Hiraga K., Suga T. (1983). On the mechnism of covalent binding of butylated hydroxytoluene to microsomal protein. Biochem. Pharmacol. 32(8), 1417–1421.
131. Nakagawa Y., Tayama K., Nakao T. i in. (1984). On the mechanism of butylated hydroxytoluene‐induced hepatic toxicity in rats. Biochem. Pharmacol. 33(16), 2669–2674.
132. NCI, National Cancer Institute (1979). Bioassay of butylated hydroxytoluene (BHT) for possible carcinogenicity. NCI‐CG‐ TR‐150, National Cancer Institute, Bethesda, MD, National Technical Information Service PB 298539.
133. NIOSH, The National Institute for Occupational Safety and Health (2021). https://www.cdc.gov/niosh/npg/npgd0246. html [dostęp: 6.05.2021].
134. OECD, Organization for Economic Cooperation and Development (2020). ENV/JM/MONO (2020) 19, https://www.oecd. org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/ JM/MONO(2020)19&docLanguage=en [dostęp: 11.05.2021].
135. Ochi T., Ohsawa M. (1985). Participation of active oxygen species in the induction of chromosomal aberrations by cadmium chloride in cultured Chinese hamster cells. Mutat. Res. 143(3), 137–142.
136. Ohta T., Moriya M., Kaneda Y. i in. (1980). Mutagenicity screening of feed additives in the microbial system. Mutat. Res. 77(1), 21–30.
137. Olsen P., Bille N., Meyer O. (1983). Hepatocellular neoplasms in rats induced by butylated hydroxytoluene (BHT). Acta Pharmacol. Toxicol. (Copenh.) 53(5), 433–434.
138. Olsen P., Meyer O., Bille N. i in. (1986). Carcinogenicity study on butylated hydroxytoluene (BHT) in Wistar rats exposed in utero. Food Chem. Toxicol. 24(1), 1–12.
139. Osmundsen P.E. (1980). Contact urticaria from nickel and plastic additives (butylhydroxytoluene, oleylamide). Contact Dermatitis 6(7), 452–454.
140. Ousji O., Sleno L. (2020). Identification of in vitro metabolites of syntheticphenolic antioxidants BHT, BHA, and TBHQ by LC-HRMS/MS. Int. J. Mol. Sci. 21(24), 9525.
141. Paschin Y.V., Bahitova L.M. (1984). Inhibition of the mutagenicity of benzo[a]pyrene in the V79/ HGPRT system by bioantioxidants. Mutat. Res. 137(1), 57–59.
142. Paschin Y.V., Bakhitova L.M., Benthen T.I. (1986). Increased antimutagenic activity of simple substituted phenols mixed with the hindered phenolic antioxidant dibunol. Food Chem. Toxicol. 24(8), 881–883.
143. Patterson R.M., Keith L.A., Stewart J. (1987). Increase in chromosomal abnormalities in Chinese hamster ovary cells treated with butylated hydroxytoluene in vitro. Toxicol. In Vitro 1(1), 55–57.
144. Peiler D., Rustemeyer T., Pflug B. i in. (2000). Allergic contact dermatitis in dental laboratory technicians. Part II: Major allergens and their clinical relevance. Dermatol. Beruf Umwelt 48(2), 48–54.
145. PubChem (2021). 2,6-Di-tert-butyl-4-methylphenol, https://pubchem.ncbi.nlm.nih.gov/#query=128-37-0 [dostęp: 11.05.2021].
146. Potenberg J., Schiffman D., Kahl R. i in. (1986). Modulation of benzo[a]pyrene‐induced morphological transformation of Syrian hamster embryo cells by butylated hydroxytoluene and butylated hydroxyanisole. Cancer Lett. 33(2), 189–198.
147. Potenberg J., von der Hude W., Bauszus M. i in. (1988). Enhancement and inhibition of benzo[a]pyrene‐induced SOS function in E. coli by synthetic antioxidants. Mutat. Res. 207(1), 7–11.
148. Powell C.J., Connelly J.C., Jones S.M. i in. (1986). Hepatic responses to the administration of high doses of BHT to the rat: their relevance to hepatocarcinogenicity. Food Chem. Toxicol. 24(10–11), 1131–1143.
149. Powell C.J., Grasso P. (1988). Characteristics of the acute hepatic damage induced by high doses of BHT. Hum. Toxicol. 7, 70.
150. Powell C.J., Connolly A.K. (1991). The site specificity and sensitivity of the rat liver to butylated hydroxytoluene‐induced damage. Toxicol. Appl. Pharmacol. 108(1), 67–77.
151. Prasad O.M., Kamra O.P. (1974). Radiosensitization of Drosophila sperm by commonly used food additives – butylated hydroxyanisole and butylated hydroxytoluene. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 25(1), 67–72.
152. Rademaker M., Forsyth A. (1989). Contact dermatitis in children. Contact Dermatitis 20, 104–107.
153. Rao V.S., Aiyar A.S. (1975). Mutagenicity evaluation studies with food additives and radiolytic products of sugars. Proceedings of the Symposium on Mutagenicity, Carcinogenicity and Teratogenicity of Chemicals, 104–114.
154. Roed‐Petersen J., Hjorth N. (1976). Contact dermatitis from antioxidants. Br. J. Dermatol. 94(3), 233–241.
155. Rozporządzenie Parlamentu Europejskiego i Rady (WE) nr 1272/2008 z dnia 16 grudnia 2008 r. w sprawie klasyfikacji, oznakowania i pakowania substancji i mieszanin, zmieniające i uchylające dyrektywy 67/548/EWG i 1999/45/WE oraz zmieniające rozporządzenie WE nr 1907/2006 ze zm. (Dz. Urz. WE L 353, 1–1355 ze zm.).
156. Röper M. i in. (2000). Acylation and alkylation. Ullmann’s Encyclopedia of industrial chemistry 7th ed. (1999-2016). New York, John Wiley & Sons. Online Posting Date: June 15, 2000.
157. Rudner E.J. (1977). North American Group results. Contact Dermatitis 3(4), 208–209.
158. Saito M., Ohkawa Y., Inui N. (1986). Retinoic acid and butylated hydroxyanisole inhibit promoter‐enhanced transformation in vitro. Cancer Lett. 33(2), 161–165.
159. Sakai A., Sato M. (1989). Improvement of carcinogen identification in BALB/3T3 cell transformation by application of a 2‐stage method. Mutat. Res. 214(2), 285–296.
160. Shirai T., Hagiwara A., Kurata Y. i in. (1982). Lack of carcinogenicity of butylated hydroxytoluene on long‐term administration to B6C3F1 mice. Food. Chem. Toxicol. 20(6), 861–865.
161. Schnuch A., Geier J., Uter W. i in. (1998). Patch testing with preservatives, antimicrobials and industrial biocides: results from a multicentre study. Br. J. Dermatol. 138(3), 467–476.
162. Shell Oil Company (1978). Chronic toxicity, teratogenicity and mutagenicity tests with dibutyl hydroxy toluene. Tokyo Metropolitan Research Laboratory of Public Health 32, NTISOTS0535892, Doc ID 88-920001303 [cyt. za: MAK 2007].
163. Sheu C.W., Cain K.T., Rushbrook C.J. i in. (1986). Tests for mutagenic effects of ammoniated glycyrrhizin, butylated hydroxytoluene, and gum arabic in rodent germ cells. Environ. Mutagen. 8, 357–367.
164. Shlian D.M., Goldstone J. (1985). Toxicity of butylated hydroxytoluene (Letter). New Engl. J. Med. 314, 648–649.
165. Søndergaard D., Olsen P. (1982). The effect of butylated hydroxytoluene (BHT) on the rat thyroid. Toxicol. Lett. 10(2–3), 239–244.
166. Stadler J.C., Lavoie D.A. (1997). Sensory irritation in mice with carpet emission chemicals. Toxicologist 36, 328 [cyt. za: ACGIH 2001].
167. Stokes J.D., Scudder C.L. (1974). The effect of butylated hydroxyanisole and butylated hydroxytoluene on behavioral development of mice. Dev. Psychobiol. 7(4), 343–350.
168. Tajima K., Yamamoto K., Mizutani T. (1981). Biotransformation of butylated hydroxytoluene (BHT) to BHT‐quinone methide in rats. Chem. Pharm. Bull. (Tokyo) 29(12), 3738–3741.
169. Tajima K., Yamamoto K., Mizutani T. (1983). Identification and determination of glutathione and glucuronide conjugates formed from butylated hydroxytoluene in rats. Chem. Pharm. Bull. (Tokyo) 31(10), 3671–3677.
170. Takahashi O., Hiraga K. (1978). Effects of low levels of butylated hydroxytoluene on the prothrombin index of male rats. Food Cosmet. Toxicol. 16(5), 475–477.
171. Takahashi O., Hiraga K. (1979). 2,6-Di-tert-butyl-4-methylene-2,5-cyclohexadienone: a hepatic metabolite of butylated hydroxytoluene in rats. Food Cosmet. Toxicol. 17(5), 451–454.
172. Takahashi O. (1992). Haemorrhages due to defective blood coagulation do not occur in mice and guinea-pigs fed butylated hydroxytoluene, but nephrotoxicity is found in mice. Food Chem. Toxicol. 30(2), 89–97.
173. Tanaka T., Oishi S., Takahashi O. (1993). Three generation toxicity study of butylated hydroxytoluene administered to mice. Toxicol. Lett. 66(3), 295–304 [cyt. za: ACGIH 2001].
174. Telford I.R., Woodruff C.S., Linford R.H. (1962). Fetal resorption in the rat as influenced by certain antioxidants. Am. J. Anat. 110, 29–36.
175. Thompson J.A., Bolton J.L., Malkinson A.M. (1991). Relationship between the metabolism of butylated hydroxytoluene (BHT) and lung tumor promotion in mice. Exp. Lung Res. 17(2), 439–453.
176. Thompson D.C., Thompson J.A., Sugumaran M. i in. (1993). Biological and toxicological consequences of quinone methide formation. Chem. Biol. Interact. 86(2), 129–162.
177. Thompson J.A., Carlson T.J., Sun Y. i in. (2001). Studies using structural analogs and inbred strain differences to support a role for quinone methide metabolites of butylated hydroxytoluene (BHT) in mouse lung tumor promotion. Toxicology 160(1–3), 197–205.
178. Trattner A., Farchi Y., David M. (2002). Cosmetics patch tests: first report from Israel. Contact Dermatitis 47(3), 180–181.
179. Trosko J.E., Yotti L.P., Dawson B. i in. (1980). In vitro assay for tumor promoters. [In:] H. Stich, R.H.C. Sam (eds.). Shortterm tests for chemical carcinogens. Springer, New York, USA, 420–427.
180. Umemura T., Kodama Y., Hioki K. i in. (2002). The mouse rasH2/BHT model as an in vivo rapid assay for lung carcinogens. Jpn. J. Cancer. Res. 93(8), 861–866.
181. Uno Y., Takasawa H., Miyagawa M. i in. (1994). An in vivo – in vitro replicative DNA synthesis (RDS) test using rat hepatocytes as an early prediction assay for non‐genotoxic hepatocarcinogens: screening of 22 know positives and 25 noncarcinogens. Mutat. Res. 320(3), 189–205.
182. US Consumer Product Safety Commission (1998a). Pulmonary/sensory irritation study of butylated hydroxytoluene (BHT) in mice. IIT Research Institute, Project No. LO6322, US Consumer Product Safety Commission, Bethesda, MD, USA [cyt. za: MAK 2007].
183. US Consumer Product Safety Commission (1998b). Hazard assessment of butylated hydroxytoluene from urethane carpet cushions. US Consumer Product Safety Commission, Bethesda, MD, USA [cyt. za: MAK 2007].
184. Wang W., Kannan K. (2019). Quantitative identification of and exposure to synthetic phenolic antioxidants, including butylated hydroxytoluene, in urine. Environ. Int. 128, 24–29.
185. WHO, World Health Organisation (1991). Toxicological evaluation of certain food additives and contaminants. WHO Technical Report Series 806, World Health Organization, Geneva, Switzerland.
186. WHO, World Health Organisation (1996). Safety evaluation of certain food additives. WHO Food Additives Series 35, World Health Organization, Geneva, Switzerland.
187. Wiebe L.I., Mercer J.R., Ryan A.J. (1978). Urinary metabolites of 3,5‐di‐(1‐[13C]methyl‐1‐methylethyl)−4‐hydroxytoluene (BHT−13C) in man. Drug. Metab. Dispos. 6(3), 296–302.
188. Williams G.M., Shimada T., McQueen C. i in. (1984). Lack of genotoxicity of butylated hydroxytoluene (BHT). Toxicologist 4, 104. Williams G.M., McQueen C.A., Tong C. (1990a). Toxicity studies of butylated hydroxyanisole and butylated hydroxytoluene: I. Genetic and cellular effects. Food. Chem. Toxicol. 28(12), 793–798.
189. Williams G.M., Wang C.X., Iatropoulos M.J. (1990b). Toxicity studies of butylated hydroxyanisole and butylated hydroxytoluene: II. Chronic feeding studies. Food Chem. Toxicol. 28(12), 799–806.
190. Williamson D., Esterez P., Witschi H.P. (1978). Studies on the pathogenesis of butylated hydroxytoluene‐induced lung damage in mice. Toxicol. Appl. Pharmacol. 43(3), 577–587.
191. Witschi H., Saheb W. (1974). Stimulation of DNA synthesis in mouse lung following intraperitoneal injection of butylated hydroxytoluene. Proc. Soc. Exp. Biol. Med. 147(3), 690–693 [cyt. za: MAK 2007].
192. Vollum D.I. (1971). Hypomelanosis from an antioxidant in polyethylene film. Arch. Dermatol. 104(1), 70–72.
193. Vorhees C.V., Butcher R.E., Brunner R.L. i in. (1981). Developmental neurobehavioural toxicity of butylated hydroxytoluene in rats. Food. Chem. Toxicol. 19, 153–162.
194. Yamamoto K., Tajima K., Mizutani T. (1979). Identification of new metabolites of butylated hydroxytoluene (BHT) in rats. J. Pharm. Dyn. 2, 164–168.
195. Yamamoto K., Tajima K., Mizutani T. (1980). The acute toxicity of butylated hydroxytoluene and its metabolites in mice. Toxicol. Lett. 6(3), 173–175.
196. Zhang R., Li J., Cui X. (2020). Tissue distribution, excretion, and metabolism of 2,6-di-tert-butyl-hydroxytoluene in mice. Sci. Total Environ. 739(Suppl. 2), 139862.
197. Zimerson E., Bruze M. (2002). Contact allergy to the monomers in p-tert-butylphenol-formaldehyde resin. Contact Dermatitis 47(3), 147–153.

Uwagi

Opracowanie rekordu ze środków MEiN, umowa nr SONP/SP/546092/2022 w ramach programu "Społeczna odpowiedzialność nauki" - moduł: Popularyzacja nauki i promocja sportu (2022-2023).

Typ dokumentu

Bibliografia

Identyfikator YADDA

bwmeta1.element.baztech-16f3960f-b658-4353-8f25-161065554d94